Description

PREJAC 60 MG

Indications

PREJAC 60 MG is primarily indicated for the treatment of premature ejaculation in adult men. This condition is characterized by ejaculation that occurs with minimal sexual stimulation, leading to distress and interpersonal difficulties. By addressing this issue, PREJAC aims to enhance sexual satisfaction and improve the quality of intimate relationships.

Mechanism of Action

PREJAC contains the active ingredient Dapoxetine, which is a selective serotonin reuptake inhibitor (SSRI). Dapoxetine works by increasing the levels of serotonin in the synaptic cleft, which helps to delay ejaculation. This mechanism not only prolongs the time to ejaculation but also enhances control over the ejaculatory reflex, providing a more satisfying sexual experience for both partners.

Pharmacological Properties

Dapoxetine is absorbed rapidly after oral administration, with peak plasma concentrations occurring approximately 1 to 2 hours post-dose. The drug has a half-life of about 1.5 hours, which allows for flexible dosing. The pharmacokinetics of Dapoxetine can be influenced by food intake; therefore, it is recommended to take PREJAC on an empty stomach for optimal absorption. The drug is primarily metabolized in the liver via the cytochrome P450 system, particularly CYP2D6, CYP3A4, and CYP2C19, and is excreted mainly in urine.

Contraindications

PREJAC 60 MG is contraindicated in individuals with a known hypersensitivity to Dapoxetine or any of its excipients. It should not be used in patients with a history of significant cardiovascular disorders, including heart failure, ischemic heart disease, or arrhythmias. Additionally, the use of PREJAC is contraindicated in conjunction with monoamine oxidase inhibitors (MAOIs) or other SSRIs, as this may lead to severe adverse effects.

Side Effects

Common side effects associated with PREJAC include nausea, dizziness, headache, and diarrhea. These effects are generally mild to moderate in intensity and tend to resolve with continued use. In rare cases, serious side effects such as syncope, seizures, or serotonin syndrome may occur. Patients should be advised to seek immediate medical attention if they experience symptoms such as confusion, hallucination, seizures, extreme changes in mood, or unusual behavior.

Dosage and Administration

The recommended starting dose of PREJAC is 30 MG, taken approximately 1 to 3 hours before anticipated sexual activity. If the initial dose is well tolerated and the desired effect is not achieved, the dose may be increased to 60 MG. However, it is not recommended to exceed this maximum dose. PREJAC should not be taken more than once in a 24-hour period. It is important for patients to follow their healthcare provider’s instructions regarding dosage and administration.

Interactions

PREJAC may interact with other medications, which can alter its effectiveness or increase the risk of adverse effects. Caution is advised when using PREJAC in conjunction with other SSRIs, MAOIs, or medications that affect serotonin levels. Additionally, drugs that are strong inhibitors of CYP2D6, CYP3A4, or CYP2C19 may increase Dapoxetine plasma concentrations, necessitating a dose adjustment. Patients should inform their healthcare providers of all medications they are currently taking, including over-the-counter products and herbal supplements.

Precautions

Patients with a history of bipolar disorder, seizures, or significant liver or kidney impairment should use PREJAC with caution. It is essential to evaluate the risk versus benefit in these populations before initiating treatment. Alcohol consumption should be minimized, as it may exacerbate side effects such as dizziness and drowsiness. Patients should also be advised to avoid operating heavy machinery or driving until they know how PREJAC affects them.

Clinical Studies

Clinical trials have demonstrated the efficacy of Dapoxetine in treating premature ejaculation. In a randomized, double-blind, placebo-controlled study, men who received PREJAC reported a significant increase in the time to ejaculation compared to those receiving placebo. Furthermore, improvements in sexual satisfaction and quality of life were noted. These studies support the use of PREJAC as a safe and effective option for managing premature ejaculation in adult men.

Conclusion

PREJAC 60 MG provides a targeted approach to managing premature ejaculation, offering patients an effective treatment option that can enhance sexual performance and satisfaction. With its rapid onset of action and favorable pharmacokinetic profile, PREJAC is a valuable addition to the therapeutic options available for this common condition. Patients are encouraged to discuss their symptoms and treatment options with their healthcare providers to determine the most appropriate course of action.